Home / Companies / Bioverativ Therapeutics Inc / Trends
Bioverativ Therapeutics Inc H-1B trends
Quarterly LCA aggregate trend points for Bioverativ Therapeutics Inc. Each point carries filing counts, distinct employers, distinct role titles, SOC coverage, wage metrics, certification counts, and source IDs when returned.
Summary
H-1B LCA filings for Bioverativ Therapeutics Inc span 2017 Q2 to 2026 Q2, peaking at 9 filings in 2019 Q2.
The most recent reported period (2026 Q2) shows 2 filings.
LCA filings are labor-condition applications certified by the U.S. Department of Labor, not active job postings or approved USCIS H-1B petitions.
| Period | LCA count | Role titles | SOC codes | Avg wage low | Avg prevailing | Certified | Certification rate |
|---|---|---|---|---|---|---|---|
| 2017 Q2 | 8 | 7 | 6 | $97,893 | $82,586 | 8 | 100.0% |
| 2018 Q2 | 8 | 8 | 4 | $109,378 | $94,655 | 8 | 100.0% |
| 2019 Q2 | 9 | 9 | 5 | $84,881 | $80,471 | 9 | 100.0% |
| 2020 Q1 | 4 | 4 | 1 | $77,423 | $77,314 | 4 | 100.0% |
| 2020 Q2 | 3 | 3 | 3 | $65,710 | $61,866 | 3 | 100.0% |
| 2020 Q3 | 6 | 6 | 5 | $113,843 | $111,377 | 6 | 100.0% |
| 2020 Q4 | 1 | 1 | 1 | $100,880 | $100,880 | 1 | 100.0% |
| 2021 Q1 | 2 | 1 | 1 | $116,896 | $97,240 | 2 | 100.0% |
| 2021 Q2 | 3 | 2 | 2 | $117,264 | $103,704 | 3 | 100.0% |
| 2021 Q3 | 5 | 4 | 4 | $99,358 | $86,935 | 5 | 100.0% |
| 2021 Q4 | 2 | 2 | 2 | $146,099 | $146,099 | 2 | 100.0% |
| 2022 Q3 | 3 | 3 | 2 | $76,793 | $75,047 | 3 | 100.0% |
| 2022 Q4 | 1 | 1 | 1 | $60,900 | $60,466 | 1 | 100.0% |
| 2023 Q1 | 1 | 1 | 1 | $108,410 | $108,410 | 1 | 100.0% |
| 2023 Q2 | 2 | 2 | 2 | $126,048 | $126,048 | 2 | 100.0% |
| 2023 Q3 | 4 | 2 | 2 | $102,971 | $94,619 | 3 | 75.0% |
| 2023 Q4 | 1 | 1 | 1 | $141,149 | $141,149 | 1 | 100.0% |
| 2025 Q3 | 1 | 1 | 1 | $104,416 | $104,416 | 1 | 100.0% |
| 2025 Q4 | 1 | 1 | 1 | $101,026 | $101,026 | 1 | 100.0% |
| 2026 Q2 | 2 | 2 | 2 | $123,417 | $123,417 | 2 | 100.0% |
Frequently asked questions
- How have H-1B filings for Bioverativ Therapeutics Inc changed over time?
- H-1B LCA filings for Bioverativ Therapeutics Inc span 2017 Q2 to 2026 Q2, peaking at 9 filings in 2019 Q2. The most recent reported period (2026 Q2) shows 2 filings. LCA filings are labor-condition applications certified by the U.S. Department of Labor, not active job postings or approved USCIS H-1B petitions.
Get this page with API
Rendered from the bluedoor H-1B Jobs API. Reproduce it:
GET https://api.bluedoor.sh/h1b-jobs/v1/trends?company=bioverativ+therapeutics+inc&metric=lca_countJSON